Lord, Abbett & Co
AMLX icon

Lord, Abbett & Co’s Amylyx Pharmaceuticals AMLX Stock Holding History

Lord, Abbett & Co’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-244,493
Closed -$5.27M – 528
2023
Q2 		$5.27M Sell
244,493
-5,549
-2% -$150K 0.02% 475
2023
Q1 		$7.34M Buy
+250,042
New +$8.69M 0.03% 437

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Lord, Abbett & Co's AMLX Position: Q3 2023 in Review

Lord, Abbett & Co sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2023, closing a stake of 244,493 shares — an estimated $5.27M sold.

Lord, Abbett & Co first reported a position in AMLX in Q1 2023 and held it in 2 quarters. The position peaked at $7.34M in Q1 2023. 170 funds tracked by Wall St. Rank hold AMLX as of Q3 2023.

  • Lord, Abbett & Co reported no remaining Amylyx Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Lord, Abbett & Co sold 244,493 Amylyx Pharmaceuticals shares in Q3 2023, an estimated $5.27M.
  • Lord, Abbett & Co first reported a position in Amylyx Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Lord, Abbett & Co's Amylyx Pharmaceuticals position peaked at $7.34M in Q1 2023.
  • 170 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2023.

Based on Lord, Abbett & Co's 13F filing for Q3 2023, filed 13 Nov 2023.